TY  - JOUR
A1  - Geissinger, Eva
A1  - Sadler, Petra
A1  - Roth, Sabine
A1  - Grieb, Tina
A1  - Puppe, Bernhard
A1  - Mueller, Nora
A1  - Reimer, Peter
A1  - Vetter-Kauczok, Claudia S.
A1  - Wenzel, Joerg
A1  - Bonzheim, Irina
A1  - Ruediger, Thomas
A1  - Mueller-Hermelink, Hans Konrad
A1  - Rosenwald, Andreas
T1  - Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30(+) T-cell lymphoproliferations
N2  - Background CD30+ T-cell lymphoproliferations comprise a spectrum of clinically heterogeneous entities, including systemic anaplastic large cell lymphomas (ALK- and ALK+) and primary cutaneous CD30+ T-cell lymphoproliferative disorders. While all these entities are characterized by proliferation of highly atypical, anaplastic CD30+ T cells, the expression of T-cell specific antigens in the tumor cells is not consistently detectable. Design and Methods We evaluated biopsies from 19 patients with primary cutaneous CD30+ lymphoproliferative disorders, 38 with ALK- and 33 with ALK+ systemic anaplastic large cell lymphoma. The biopsies were examined for the expression of T-cell receptoraβ/CD3 complex (CD3γ, δ, ε, ζ), transcription factors regulating T-cell receptor expression (ATF1, ATF2, TCF-1, TCF-1a/LEF-1, Ets1), and molecules of T-cell receptor-associated signaling cascades (Lck, ZAP-70, LAT, bcl-10, Carma1, NFATc1, c-Jun, c-Fos, Syk) using immunohistochemistry. Results In comparison to the pattern in 20 peripheral T-cell lymphomas, not otherwise specified, we detected a highly disturbed expression of the T-cell receptor/CD3 complex, TCF-1, TCF- 1a/LEF-1, Lck, ZAP-70, LAT, NFATc1, c-Jun, c-Fos and Syk in most of the systemic anaplastic large cell lymphomas. In addition, primary cutaneous CD30+ lymphoproliferative disorders showed such a similar expression pattern to that of systemic anaplastic large cell lymphomas, that none of the markers we investigated can reliably distinguish between these CD30+ T-cell lymphoproliferations. Conclusions Severely altered expression of the T-cell receptor/CD3 complex, T-cell receptor-associated transcription factors and signal transduction molecules is a common characteristic of systemic and cutaneous CD30+ lymphoproliferations, although the clinical behavior of these entities is very different. Since peripheral T-cell lymphomas, not otherwise specified retain the full expression program required for functioning T-cell receptor signaling, the differential expression of a subset of these markers might be of diagnostic utility in distinguishing peripheral T-cell lymphomas, not otherwise specified from the entire group of CD30+ lymphoproliferations.
KW  - Medizin
KW  - systemic and cutaneous CD30+ lymphoproliferations
KW  - anaplastic large cell lymphoma
KW  - lymphomatoid papulosis
KW  - ALCL
KW  - LyP
KW  - TCR
Y1  - 2010
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68179
ER  - 
TY  - JOUR
A1  - Patel, Suketu
A1  - Murphy, Derek
A1  - Haralmbieva, Eugenia
A1  - Abdulla, Zainalabideen A.
A1  - Wong, Kah Keng
A1  - Chen, Hong
A1  - Gould, Edith
A1  - Roncador, Giovanna
A1  - Hatton, Chris S. R.
A1  - Anderson, Amanda P.
A1  - Banham, Alison H.
A1  - Pulford, Karen
T1  - Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas
JF  - Biomarker Insights
N2  - FAS-associated protein with death domain (FADD) is a major adaptor protein involved in extrinsic apoptosis, embryogenesis, and lymphocyte homeostasis. Although abnormalities of the FADD/death receptor apoptotic pathways have been established in tumorigenesis, fewer studies have analyzed the expression and role of phosphorylated FADD (pFADD). Our identification of FADD as a lymphoma-associated autoantigen in T-cell lymphoma patients raises the possibility that pFADD, with its correlation with cell cycle, may possess role(s) in human T-cell lymphoma development. This immunohistochemical study investigated pFADD protein expression in a range of normal tissues and lymphomas, particularly T-cell lymphomas that require improved therapies. Whereas pFADD was expressed only in scattered normal T cells, it was detected at high levels in T-cell lymphomas (eg, 84% anaplastic large cell lymphoma and 65% peripheral T cell lymphomas, not otherwise specified). The increased expression of pFADD supports further study of its clinical relevance and role in lymphomagenesis, highlighting phosphorylation of FADD as a potential therapeutic target.
KW  - autoantigen
KW  - lymphoma
KW  - pFADD
KW  - PTCL
KW  - FADD
KW  - ALCL
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121403
SN  - 1177-2719
VL  - 9
ER  -